Thinking globally, acting locally

Why BeiGene’s Pfizer hire indicates the China market is ready for innovator drugs

BeiGene Ltd.’s hire of Pfizer Inc. veteran Xiaobing Wu is one of the loudest signals to date that regulatory and reimbursement reforms have made it attractive to develop and commercialize innovative drugs in China. Wu’s extensive network and market access expertise should help BeiGene make the most of the new opportunity.

Wu joins BeiGene as general manager of China and president, after serving since 2004 in a similar capacity at Pfizer, and before that at Wyeth, which Pfizer acquired in 2009. In his last position as country manager at Pfizer China and regional president of Pfizer Essential Health for greater China, he oversaw Pfizer’s operations and portfolio, and conducted projects and partnerships to facilitate patient access to medicines.

Under his watch, Pfizer became the number one multinational pharma in China by sales.

CEO John Oyler said Wu will guide BeiGene as it scales up in China, which it sees

Read the full 1488 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE